SCHEMBL526317

SCHEMBL526317

O=C(O)CCn1ccc2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.73
KMT2A Q03164 1/20 0.69
CDK4 P11802 4/20 0.66
CCND1 P24385 4/20 0.66
KMO O15229 2/20 0.62
MAPK1 P28482 3/20 0.58
HSD17B10 Q99714 1/20 0.56
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
TERT O14746 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
EGLN3 Q9H6Z9 1/20 0.53
CREBBP Q92793 1/20 0.53
MTNR1A P48039 1/20 0.52
MTNR1B P49286 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29684637 1.00 LMNA (0.73) LMNAKMT2ACDK4CCND1KMO
SCHEMBL29560163 0.90 CDK4 (0.68) LMNAKMT2ACDK4CCND1KMO
SCHEMBL1967792 0.90 CDK4 (0.68) LMNAKMT2ACDK4CCND1KMO
SCHEMBL1269116 0.88 CDK4 (0.71) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL19783673 0.87 CDK4 (0.72) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL30582936 0.87 CDK4 (0.72) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL12881191 0.84 LMNA (0.71) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL7349228 0.84 LMNA (1.00) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL10203635 0.83 LMNA (0.69) LMNAKMT2ACDK4CCND1MAPK1
SCHEMBL31370177 0.82 MAPK1 (0.62) LMNAKMT2ACDK4CCND1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456699-A Seawater alternation resistant marine antifouling paint and preparation method thereof 嘉兴学院 2022-05-10 CN claimed
EP-2509424-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2012-10-17 EP claimed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO claimed
EP-0715627-A1 INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS Pfizer Limited (GB) 1996-06-12 EP claimed
WO-1995006046-A1 INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS PFIZER LIMITED (GB) 1995-03-02 WO claimed
CN-116496200-B Lysosome/mitochondrion bicolor fluorescent probe with pH responsiveness and preparation method and application thereof 中山大学 2024-07-05 CN disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
EP-3625316-B1 DISPERSANTS, METHOD OF MAKING, AND USING SAME CHEVRON ORONITE CO (US) 2023-08-23 EP disclosed
CN-116496200-A Lysosome/mitochondrion bicolor fluorescent probe with pH responsiveness and preparation method and application thereof 中山大学 2023-07-28 CN disclosed
US-11583517-B2 Dual antagonist of PGD2/DPr2 and Thromboxane A2/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis APPLIED MEDICAL TECHNOLOGIES LLC (US) 2023-02-21 US disclosed
EP-4126050-A1 DUAL ANTAGONIST OF PGD2/DPR2 AND THROMBOXANE A2/TPR RECEPTORS AND USE FOR TREATMENT OF MALAPTIVE IMMUNE RESPONSE OR THROMBOTIC DIATHESIS Applied Medical Technologies LLC (US) 2023-02-08 EP disclosed
WO-1997034922-A1 TREATMENT OF PREECLAMPSIA, ECLAMPSIA OR PRETERM LABOR WITH CALCITONIN GENE RELATED PEPTIDE AND RELATED DRUGS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1997-09-25 WO disclosed
EP-0715627-A1 INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS Pfizer Limited (GB) 1996-06-12 EP disclosed
EP-0708647-A1 COMBINATION OF A PROGESTATIONAL AGENT AND A NITRIC OXIDE SYNTHASE SUBSTRATE AND/OR DONOR FOR THE TREATMENT OF PREECLAMPSIA AND PRETERM LABOR SCHERING AKTIENGESELLSCHAFT (DE) 1996-05-01 EP disclosed
US-5389661-A Treats hypertension, heart failure, glaucoma and hyperaldosteronism WARNER-LAMBERT COMPANY (US) 1995-02-14 US disclosed
WO-1995002408-A1 COMBINATION OF A PROGESTATIONAL AGENT AND A NITRIC OXIDE SYNTHASE SUBSTRATE AND/OR DONOR FOR THE TREATMENT OF PREECLAMPSIA AND PRETERM LABOR SCHERING AKTIENGESELLSCHAFT (DE) 1995-01-26 WO disclosed
US-5322950-A Treating hypertension, hyperaldosteronism, glaucoma, heart failure WARNER-LAMBERT COMPANY (US) 1994-06-21 US disclosed
WO-1994011361-A1 PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES THE UPJOHN COMPANY (US) 1994-05-26 WO disclosed
US-4273782-A FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES PFIZER INC. (US) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 LMNA 4199/4885KMT2A 4196/4885CDK4 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.